Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.
Lilly CEO: U.K. has gone from biopharma leader to laggard

32
Lilly CEO Dave Ricks explains why pricing dynamics in the U.K. make it a very unattractive place for Lilly to invest.